山西汾酒(600809.SH):華創鑫睿擬減持不超過800萬股
格隆匯5月20日丨山西汾酒(600809.SH)公佈,截止本公吿日,華創鑫睿(香港)有限公司(簡稱“華創鑫睿”)持有公司股份136,116,296股,佔公司總股本的比例為11.16%,為公司持股5%以上股東。其中:華潤創業有限公司(簡稱“華潤創業”)持有華創鑫睿80.62%股份,華潤創業聯和基金一期(有限合夥)(簡稱“聯和基金”)持有華創鑫睿19.38%股份。
根據聯和基金相關合作協議,其面臨基金到期退出安排,需要減持其間接持有的公司股份,因此華創鑫睿本次擬通過大宗交易方式減持不超過800萬股,自本次減持計劃公開披露之日起15個交易日後的3個月內(含3個月期滿當日)實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.